Merck-Moderna Vaccine Cuts Melanoma Death or Recurrence Risk 42%
Trial data show the mRNA vaccine, combined with a widely used immunotherapy, cut melanoma disease-spread risk by 38%.
Data from a large trial showed that an mRNA cancer vaccine developed by Moderna NASDAQ:MRNA and Merck NYSE:MRK, when combined with a widely used immunotherapy, reduced the risk of melanoma recurrence or death by 42% and the risk of disease spread by 38%. The findings could potentially open the way to a new era of personalized…